ArticleOncotarget2017

Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer.

Fei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.